gMG

Nephrology·MeSH: Adrenal Insufficiency

7 drugs in development·5 companies·7 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
rystiggo	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
Ultomiris	Xencor Inc (XNCR)

Phase 2(2)

Drug	Company
m281	MOMENTA PHARMACEUTICALS INC (MNTA)
rese-cel	Cabaletta Bio, Inc. (CABA)

Phase 1(3)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)
CABA-201	Filana Therapeutics Inc. (FLNA)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)

BioSniper tracks 7 drugs in development for gMG across 5 companies.

There are 7 clinical trials targeting gMG tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.